New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
06:08 EDTACHNAchillion announces clinical results for ACH-3102
Achillion announced updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 including subjects who had Y93 mutations at baseline. A second oral presentation on ACH-3102 was made at APASL 2014 that discussed clinical virology and the lack of virologic breakthrough that was observed in the novel Phase 2 clinical trial evaluating ACH-3102 with ribavirin for patients with treatment-na´ve genotype 1b HCV. Despite the presence of up to six linked mutations identified at baseline in the NS5A protein, ACH-3102, without the co-administration of interferon or a second direct-acting antiviral, was able to suppress viral replication with no virologic breakthrough observed during 12 weeks of treatment.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
06:12 EDTACHNAchillion plans to initiate Sparta doublet regimen clinical trial in 1H15
Plans to initiate in the first half of 2015 a clinical trial with ACH-3422 in combination with ACH-3102 for patients with treatment-na´ve genotype 1 HCV for treatment durations of 6, 8 and 12 weeks. SVR4 results are expected in the second half of 2015. Plans to initiate during the first quarter a Phase 1 proof-of-concept trial evaluating the anti-viral activity of ACH-3422 for HCV genotypes 2 and 3. Results are anticipated during the second quarter of 2015. Expects to initiate during the first half of 2015 a proxy triplet trial evaluating ACH-3102 and sovaprevir with sofosbuvir for a treatment duration of 4 weeks. SVR4 results are expected in the second half of 2015; and expects to initiate by the end of 2015 a pharmacokinetic and viral kinetic study of ACH-3422, ACH-3102 and sovaprevir in patients with treatment-na´ve genotype 1 HCV. Expects to nominate a novel orally-administered complement factor D inhibitor and advance into a phase I clinical trial by the end of 2015.
06:11 EDTACHNAchillion sees FY15 EPS (95c), consensus (83c)
Subscribe for More Information
06:11 EDTACHNAchillion reports Q4 EPS (21c), consensus (18c)
Subscribe for More Information
March 4, 2015
10:01 EDTACHNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:35 EDTACHNAchillion initiated with an Underweight at Barclays
Barclays started shares of Achillion with an Underweight rating and $8 price target citing the company's lateness to the hepatitis C market as well as competition in the space.
February 24, 2015
10:34 EDTACHNAchillion March calls active on renewed takeover chatter
Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:22 EDTACHNRumor: Achillion moves positive on renewed takeover chatter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use